Open Access
Review
The Role of the CREB Signaling Pathway in Tumor Development and Therapeutic Potential
Qunlong Jin1, 2, †
, Youheng Jiang1, 2, †
, Zhiheng Zhang1, 3, †
, Yanming Yang1
, Zhang Fu1
, Yunfeng Gao1, 4
, Ningning Li1, 5
, Yulong He2, *
, Changxue Li1, 2, *
Author Information
Submitted: 2 May 2024 | Revised: 19 May 2024 | Accepted: 20 May 2024 | Published: 11 Jun 2024
Abstract
The cAMP response element-binding protein (CREB) is a multifunctional transcription factor belonging to the basic leucine zipper (bZIP) family of proteins. It regulates the expression of target genes by binding to the cAMP response element (CRE) on DNA. The activation of CREB in cells typically depends on its phosphorylation, mediated by kinases activated by various signaling pathways, such as the cAMP-dependent protein kinase A (PKA) pathway and the PI3K-AKT pathway. CREB regulates genes involved in various cellular functions, including cell growth, differentiation, survival, as well as the development and plasticity of the nervous system. Therefore, CREB plays a key role in the development of neurological diseases, oncology, and other diseases. This review aims to systematically elucidate the structure and regulatory mechanisms of CREB, its biological function in tumors, and the potential of targeting the CREB signaling pathway in anti-tumor therapy, with the hope of providing new strategies and targets for cancer treatment.
Keywords
References
1.
Sung, H.; Ferlay, J.; Siegel, R.L.; et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249.
2.
Hoelder, S.; Clarke, P.A.; Workman, P. Discovery of small molecule cancer drugs: Successes, challenges and opportunities. Mol. Oncol. 2012, 6, 155–176.
3.
Hutchinson, L.; Kirk, R. High drug attrition rates--where are we going wrong? Nat. Rev. Clin. Oncol. 2011, 8, 189–190.
4.
Nikolaou, M.; Pavlopoulou, A.; Georgakilas, A.G.; et al. The challenge of drug resistance in cancer treatment: A current overview. Clin. Exp. Metastasis 2018, 35, 309–318.
5.
Toyota, M.; Suzuki, H.; Yamamoto, E.; et al. Integrated analysis of genetic and epigenetic alterations in cancer. Epigenomics 2009, 1, 291–299.
6.
Sieber, O.; Heinimann, K.; Tomlinson, I. Genomic stability and tumorigenesis. Semin Cancer Biol. 2005, 15, 61–66.
7.
Martincorena, I.; Campbell, P.J. Somatic mutation in cancer and normal cells. Science 2015, 349, 1483–1489.
8.
Lambert, S.A.; Jolma, A.; Campitelli, L.F.; et al. The Human Transcription Factors. Cell 2018, 172, 650–665.
9.
Bushweller, J.H. Targeting transcription factors in cancer - from undruggable to reality. Nat. Rev. Cancer 2019, 19, 611–624.
10.
Montminy, M.R.; Bilezikjian, L.M. Binding of a nuclear protein to the cyclic-AMP response element of the somatostatin gene. Nature 1987, 328, 175–178.
11.
Zhang, X.; Odom, D.T.; Koo, S.H.; et al. Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 4459–4464.
12.
Shaywitz, A.J.; Greenberg, M.E. CREB: A stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu. Rev. Biochem. 1999, 68, 821–861.
13.
Srinivasan, S.; Totiger, T.; Shi, C.; et al. Tobacco Carcinogen-Induced Production of GM-CSF Activates CREB to Promote Pancreatic Cancer. Cancer Res. 2018, 78, 6146–6158.
14.
Felinski, E.A.; Quinn, P.G. The coactivator dTAF(II)110/hTAF(II)135 is sufficient to recruit a polymerase complex and activate basal transcription mediated by CREB. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 13078–13083.
15.
Mayr, B.M.; Guzman, E.; Montminy, M. Glutamine rich and basic region/leucine zipper (bZIP) domains stabilize cAMP-response element-binding protein (CREB) binding to chromatin. J. Biol. Chem. 2005, 280, 15103–15110.
16.
Schumacher, M.A.; Goodman, R.H.; Brennan, R.G. The structure of a CREB bZIP. somatostatin CRE complex reveals the basis for selective dimerization and divalent cation-enhanced DNA binding. J. Biol. Chem. 2000, 275, 35242–35247.
17.
Dou, Y.; Kawaler, E.A.; Zhou, D.C.; et al. Proteogenomic Characterization of Endometrial Carcinoma. Cell 2020, 180, 729–748.e726.
18.
Abida, W.; Cyrta, J.; Heller, G.; et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc. Natl. Acad. Sci. U.S.A. 2019, 116, 11428–11436.
19.
Ghandi, M.; Huang, F.W.; Jané-Valbuena, J.; et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 2019, 569, 503–508.
20.
Sloan, E.A.; Chiang, J.; Villanueva-Meyer, J.E.; et al. Intracranial mesenchymal tumor with FET-CREB fusion-A unifying diagnosis for the spectrum of intracranial myxoid mesenchymal tumors and angiomatoid fibrous histiocytoma-like neoplasms. Brain Pathol. 2021, 31, e12918.
21.
Hill, M.; Tran, N. miRNA interplay: Mechanisms and consequences in cancer. Dis. Model Mech. 2021, 14, dmm047662.
22.
Tan, X.; Wang, S.; Yang, B.; et al. The CREB-miR-9 negative feedback minicircuitry coordinates the migration and proliferation of glioma cells. PLoS ONE 2012, 7, e49570.
23.
Cohen, P. The origins of protein phosphorylation. Nat. Cell Biol. 2002, 4, E127–E130.
24.
Johannessen, M.; Delghandi, M.P.; Moens, U. What turns CREB on? Cell. Signalling 2004, 16, 1211–1227.
25.
Thakur, J.K.; Yadav, A.; Yadav, G. Molecular recognition by the KIX domain and its role in gene regulation. Nucleic Acids Res. 2014, 42, 2112–2125.
26.
Shaywitz, A.J.; Dove, S.L.; Kornhauser, J.M.; et al. Magnitude of the CREB-dependent transcriptional response is determined by the strength of the interaction between the kinase-inducible domain of CREB and the KIX domain of CREB-binding protein. Mol. Cell. Biol. 2000, 20, 9409–9422.
27.
Chrivia, J.C.; Kwok, R.P.; Lamb, N.; et al. Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 1993, 365, 855–859.
28.
Balogh, A.; Németh, M.; Koloszár, I.; et al. Overexpression of CREB protein protects from tunicamycin-induced apoptosis in various rat cell types. Apoptosis 2014, 19, 1080–1098.
29.
Niederberger, E.; Ehnert, C.; Gao, W.; et al. The impact of CREB and its phosphorylation at Ser142 on inflammatory nociception. Biochem. Biophys. Res. Commun. 2007, 362, 75–80.
30.
Shanware, N.P.; Trinh, A.T.; Williams, L.M.; et al. Coregulated ataxia telangiectasia-mutated and casein kinase sites modulate cAMP-response element-binding protein-coactivator interactions in response to DNA damage. J. Biol. Chem. 2007, 282, 6283–6291.
31.
Shanware, N.P.; Williams, L.M.; Bowler, M.J.; et al. Non-specific in vivo inhibition of CK1 by the pyridinyl imidazole p38 inhibitors SB 203580 and SB 202190. BMB Rep. 2009, 42, 142–147.
32.
Pan, S.; Chen, R. Pathological implication of protein post-translational modifications in cancer. Mol. Aspects. Med. 2022, 86, 101097.
33.
Steven, A.; Friedrich, M.; Jank, P.; et al. What turns CREB on? And off? And why does it matter? Cell. Mol. Life Sci. 2020, 77, 4049–4067.
34.
Lu, S.; Yin, X.; Wang, J.; et al. SIRT1 regulates O-GlcNAcylation of tau through OGT. Aging 2020, 12, 7042–7055.
35.
Liu, X.F.; Tang, C.X.; Zhang, L.; et al. Down-Regulated CUEDC2 Increases GDNF Expression by Stabilizing CREB Through Reducing Its Ubiquitination in Glioma. Neurochem. Res. 2020, 45, 2915–2925.
36.
Zhang, N.; Shi, L.; Wang, Y. CREB-associated glycosylation and function in human disease. Adv. Clin. Exp. Med. 2022, 31, 1289–1297.
37.
Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100, 57–70.
38.
Hanahan, D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022, 12, 31–46.
39.
Cheng, N.; Chytil, A.; Shyr, Y.; et al. Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion. Mol. Cancer Res. 2008, 6, 1521–1533.
40.
Ansari, K.M.; Rundhaug, J.E.; Fischer, S.M. Multiple signaling pathways are responsible for prostaglandin E2-induced murine keratinocyte proliferation. Mol. Cancer Res. 2008, 6, 1003–1016.
41.
Linder, M.; Glitzner, E.; Srivatsa, S.; et al. EGFR is required for FOS-dependent bone tumor development via RSK2/CREB signaling. EMBO Mol. Med. 2018, 10, e9408.
42.
Wan, X.; Zhou, M.; Huang, F.; et al. AKT1-CREB stimulation of PDGFRα expression is pivotal for PTEN deficient tumor development. Cell Death Dis. 2021, 12, 172.
43.
Adams, J.M.; Cory, S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007, 26, 1324–1337.
44.
Walia, M.K.; Ho, P.M.; Taylor, S.; et al. Activation of PTHrP-cAMP-CREB1 signaling following p53 loss is essential for osteosarcoma initiation and maintenance. Elife 2016, 5, e13446.
45.
Walia, M.K.; Taylor, S.; Ho, P.W.M.; et al. Tolerance to sustained activation of the cAMP/Creb pathway activity in osteoblastic cells is enabled by loss of p53. Cell Death Dis. 2018, 9, 844.
46.
Wang, H.; Ren, R.; Yang, Z.; et al. The COL11A1/Akt/CREB signaling axis enables mitochondrial-mediated apoptotic evasion to promote chemoresistance in pancreatic cancer cells through modulating BAX/BCL-2 function. J. Cancer 2021, 12, 1406–1420.
47.
Levy, J.M.M.; Towers, C.G.; Thorburn, A. Targeting autophagy in cancer. Nat. Rev. Cancer 2017, 17, 528–542.
48.
Chen, S.J.; Bao, L.; Keefer, K.; et al. Transient receptor potential ion channel TRPM2 promotes AML proliferation and survival through modulation of mitochondrial function, ROS, and autophagy. Cell Death Dis. 2020, 11, 247.
49.
Wang, M.; Liu, K.; Bu, H.; et al. Purple sweet potato delphinidin-3-rutin represses glioma proliferation by inducing miR-20b-5p/Atg7-dependent cytostatic autophagy. Mol. Ther. Oncolytics 2022, 26, 314–329.
50.
Fares, J.; Fares, M.Y.; Khachfe, H.H.; et al. Molecular principles of metastasis: A hallmark of cancer revisited. Signal Transduct Target Ther. 2020, 5, 28.
51.
Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674.
52.
Xu, X.; Zhu, Y.; Liang, Z.; et al. c-Met and CREB1 are involved in miR-433-mediated inhibition of the epithelial-mesenchymal transition in bladder cancer by regulating Akt/GSK-3β/Snail signaling. Cell Death Dis. 2016, 7, e2088.
53.
Wu, D.; Zhau, H.E.; Huang, W.C.; et al. cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: Implication in human prostate cancer bone metastasis. Oncogene 2007, 26, 5070–5077.
54.
Karamanos, N.K.; Theocharis, A.D.; Piperigkou, Z.; et al. A guide to the composition and functions of the extracellular matrix. FEBS J. 2021, 288, 6850–6912.
55.
Kessenbrock, K.; Plaks, V.; Werb, Z. Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell 2010, 141, 52–67.
56.
Park, J.K.; Park, S.H.; So, K.; et al. ICAM-3 enhances the migratory and invasive potential of human non-small cell lung cancer cells by inducing MMP-2 and MMP-9 via Akt and CREB. Int. J. Oncol. 2010, 36, 181–192.
57.
Li, J.; Liu, X.; Wang, W.; et al. MSK1 promotes cell proliferation and metastasis in uveal melanoma by phosphorylating CREB. Arch. Med. Sci. 2020, 16, 1176–1188.
58.
Meng, X.Y.; Zhang, H.Z.; Ren, Y.Y.; et al. Pinin promotes tumor progression via activating CREB through PI3K/AKT and ERK/MAPK pathway in prostate cancer. Am. J. Cancer Res. 2021, 11, 1286–1303.
59.
Hu, S.; Wang, L.; Zhang, X.; et al. Autophagy induces transforming growth factor-β-dependent epithelial-mesenchymal transition in hepatocarcinoma cells through cAMP response element binding signalling. J. Cell Mol. Med. 2018, 22, 5518–5532.
60.
Fujishita, T.; Kojima, Y.; Kajino-Sakamoto, R.; et al. The cAMP/PKA/CREB and TGFβ/SMAD4 Pathways Regulate Stemness and Metastatic Potential in Colorectal Cancer Cells. Cancer Res. 2022, 82, 4179–4190.
61.
Viallard, C.; Larrivée, B. Tumor angiogenesis and vascular normalization: Alternative therapeutic targets. Angiogenesis 2017, 20, 409–426.
62.
Apte, R.S.; Chen, D.S.; Ferrara, N. VEGF in Signaling and Disease: Beyond Discovery and Development. Cell 2019, 176, 1248–1264.
63.
Zhao, D.; Desai, S.; Zeng, H. VEGF stimulates PKD-mediated CREB-dependent orphan nuclear receptor Nurr1 expression: Role in VEGF-induced angiogenesis. Int. J. Cancer 2011, 128, 2602–2612.
64.
Kaur, S.; Bronson, S.M.; Pal-Nath, D.; et al. Functions of Thrombospondin-1 in the Tumor Microenvironment. Int. J. Mol. Sci. 2021, 22, 4570.
65.
Hulsurkar, M.; Li, Z.; Zhang, Y.; et al. Beta-adrenergic signaling promotes tumor angiogenesis and prostate cancer progression through HDAC2-mediated suppression of thrombospondin-1. Oncogene 2017, 36, 1525–1536.
66.
Zhang, Y.; Zheng, D.; Zhou, T.; et al. Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers. Nat. Commun. 2018, 9, 4080.
67.
Meyuhas, R.; Pikarsky, E.; Tavor, E.; et al. A Key role for cyclic AMP-responsive element binding protein in hypoxia-mediated activation of the angiogenesis factor CCN1 (CYR61) in Tumor cells. Mol. Cancer Res. 2008, 6, 1397–1409.
68.
Dobroff, A.S.; Wang, H.; Melnikova, V.O.; et al. Silencing cAMP-response element-binding protein (CREB) identifies CYR61 as a tumor suppressor gene in melanoma. J. Biol. Chem. 2009, 284, 26194–26206.
69.
Park, J.H.; Pyun, W.Y.; Park, H.W. Cancer Metabolism: Phenotype, Signaling and Therapeutic Targets. Cells 2020, 9, 2308.
70.
Liberti, M.V.; Locasale, J.W. The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem. Sci. 2016, 41, 211–218.
71.
Vaupel, P.; Schmidberger, H.; Mayer, A. The Warburg effect: Essential part of metabolic reprogramming and central contributor to cancer progression. Int. J. Radiat. Biol. 2019, 95, 912–919.
72.
Liu, Z.; Chen, X.; Wang, Y.; et al. PDK4 protein promotes tumorigenesis through activation of cAMP-response element-binding protein (CREB)-Ras homolog enriched in brain (RHEB)-mTORC1 signaling cascade. J. Biol. Chem. 2014, 289, 29739–29749.
73.
Gao, R.; Li, D.; Xun, J.; et al. CD44ICD promotes breast cancer stemness via PFKFB4-mediated glucose metabolism. Theranostics 2018, 8, 6248–6262.
74.
Kuo, M.H.; Chang, W.W.; Yeh, B.W.; et al. Glucose Transporter 3 is Essential for the Survival of Breast Cancer Cells in the Brain. Cells 2019, 8, 1568.
75.
Yu, T.; Yang, G.; Hou, Y.; et al. Cytoplasmic GPER translocation in cancer-associated fibroblasts mediates cAMP/PKA/CREB/glycolytic axis to confer tumor cells with multidrug resistance. Oncogene 2017, 36, 2131–2145.
76.
Xing, F.; Luan, Y.; Cai, J.; et al. The Anti-Warburg Effect Elicited by the cAMP-PGC1α Pathway Drives Differentiation of Glioblastoma Cells into Astrocytes. Cell Rep. 2018, 23, 2832–2833.
77.
Dunn, G.P.; Bruce, A.T.; Ikeda, H.; et al. Cancer immunoediting: From immunosurveillance to tumor escape. Nat. Immunol. 2002, 3, 991–998.
78.
Swann, J.B.; Smyth, M.J. Immune surveillance of tumors. J. Clin. Invest. 2007, 117, 1137–1146.
79.
Jayasingam, S.D.; Citartan, M.; Thang, T.H.; et al. Evaluating the Polarization of Tumor-Associated Macrophages into M1 and M2 Phenotypes in Human Cancer Tissue: Technicalities and Challenges in Routine Clinical Practice. Front. Oncol. 2019, 9, 1512.
80.
Jiang, H.; Wei, H.; Wang, H.; et al. Zeb1-induced metabolic reprogramming of glycolysis is essential for macrophage polarization in breast cancer. Cell Death Dis. 2022, 13, 206.
81.
Cheng, Y.; Zhu, Y.; Xu, J.; et al. PKN2 in colon cancer cells inhibits M2 phenotype polarization of tumor-associated macrophages via regulating DUSP6-Erk1/2 pathway. Mol. Cancer 2018, 17, 13.
82.
Sun, C.; Wang, B.; Hao, S. Adenosine-A2A Receptor Pathway in Cancer Immunotherapy. Front. Immunol. 2022, 13, 837230.
83.
Mastelic-Gavillet, B.; Navarro Rodrigo, B.; Décombaz, L.; et al. Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8(+) T cells. J. Immunother Cancer 2019, 7, 257.
84.
Masjedi, A.; Hassannia, H.; Atyabi, F.; et al. Downregulation of A2AR by siRNA loaded PEG-chitosan-lactate nanoparticles restores the T cell mediated anti-tumor responses through blockage of PKA/CREB signaling pathway. Int. J. Biol. Macromol. 2019, 133, 436–445.
85.
Dziedzic, K.; Węgrzyn, P.; Gałęzowski, M.; et al. Release of adenosine-induced immunosuppression: Comprehensive characterization of dual A(2A)/A(2B) receptor antagonist. Int. Immunopharmacol. 2021, 96, 107645.
86.
Sauer, M.; Schuldner, M.; Hoffmann, N.; et al. CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells. Oncogene 2017, 36, 933–941.
87.
Newton, K.; Dixit, V.M. Signaling in innate immunity and inflammation. Cold Spring Harb Perspect. Biol. 2012, 4, a006049. doi:10.1101/cshperspect.a006049 From NLM.
88.
Wen, A.Y.; Sakamoto, K.M.; Miller, L.S. The role of the transcription factor CREB in immune function. J. Immunol. 2010, 185, 6413–6419.
89.
Westbom, C.M.; Shukla, A.; MacPherson, M.B.; et al. CREB-induced inflammation is important for malignant mesothelioma growth. Am. J. Pathol. 2014, 184, 2816–2827.
90.
Pan, P.; Oshima, K.; Huang, Y.W.; et al. Loss of FFAR2 promotes colon cancer by epigenetic dysregulation of inflammation suppressors. Int. J. Cancer 2018, 143, 886–896.
91.
Resende, C.; Regalo, G.; Durães, C.; et al. Interleukin-1B signalling leads to increased survival of gastric carcinoma cells through a CREB-C/EBPβ-associated mechanism. Gastric Cancer 2016, 19, 74–84.
92.
Lapidot, T.; Sirard, C.; Vormoor, J.; et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367, 645–648.
93.
Zhou, G.; Latchoumanin, O.; Bagdesar, M.; et al. Aptamer-Based Therapeutic Approaches to Target Cancer Stem Cells. Theranostics 2017, 7, 3948–3961.
94.
Daniel, P.M.; Filiz, G.; Brown, D.V.; et al. PI3K activation in neural stem cells drives tumorigenesis which can be ameliorated by targeting the cAMP response element binding protein. Neuro. Oncol. 2018, 20, 1344–1355.
95.
Duan, S.; Yuan, G.; Liu, X.; et al. PTEN deficiency reprogrammes human neural stem cells towards a glioblastoma stem cell-like phenotype. Nat. Commun. 2015, 6, 10068.
96.
Eyre, R.; Alférez, D.G.; Santiago-Gómez, A.; et al. Microenvironmental IL1β promotes breast cancer metastatic colonisation in the bone via activation of Wnt signalling. Nat. Commun. 2019, 10, 5016.
97.
Zhang, Z.; Qiu, N.; Yin, J.; et al. SRGN crosstalks with YAP to maintain chemoresistance and stemness in breast cancer cells by modulating HDAC2 expression. Theranostics 2020, 10, 4290–4307.
98.
Lv, Y.; Cang, W.; Li, Q.; et al. Erlotinib overcomes paclitaxel-resistant cancer stem cells by blocking the EGFR-CREB/GRβ-IL-6 axis in MUC1-positive cervical cancer. Oncogenesis 2019, 8, 70.
99.
Pigazzi, M.; Manara, E.; Baron, E.; et al. ICER expression inhibits leukemia phenotype and controls tumor progression. Leukemia 2008, 22, 2217–2225.
100.
Molina, C.A.; Foulkes, N.S.; Lalli, E.; et al. Inducibility and negative autoregulation of CREM: An alternative promoter directs the expression of ICER, an early response repressor. Cell 1993, 75, 875–886.
101.
Xie, S.; Price, J.E.; Luca, M.; et al. Dominant-negative CREB inhibits tumor growth and metastasis of human melanoma cells. Oncogene 1997, 15, 2069–2075.
102.
Zhang, H.; Yang, S.; Wang, J.; et al. Blockade of AMPK-Mediated cAMP-PKA-CREB/ATF1 Signaling Synergizes with Aspirin to Inhibit Hepatocellular Carcinoma. Cancers 2021, 13, 1738.
103.
Pigazzi, M.; Manara, E.; Baron, E.; et al. miR-34b targets cyclic AMP-responsive element binding protein in acute myeloid leukemia. Cancer Res. 2009, 69, 2471–2478.
104.
Illiano, M.; Nigro, E.; Sapio, L.; et al. Adiponectin down-regulates CREB and inhibits proliferation of A549 lung cancer cells. Pulm. Pharmacol. Ther. 2017, 45, 114–120.
105.
Best, J.L.; Amezcua, C.A.; Mayr, B.; et al. Identification of small-molecule antagonists that inhibit an activator: Coactivator interaction. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 17622–17627.
106.
De Guzman, R.N.; Goto, N.K.; Dyson, H.J.; et al. Structural basis for cooperative transcription factor binding to the CBP coactivator. J. Mol. Biol. 2006, 355, 1005–1013.
107.
Uttarkar, S.; Dukare, S.; Bopp, B.; et al. Naphthol AS-E Phosphate Inhibits the Activity of the Transcription Factor Myb by Blocking the Interaction with the KIX Domain of the Coactivator p300. Mol. Cancer Ther. 2015, 14, 1276–1285.
108.
Sun, H.; Chung, W.C.; Ryu, S.H.; et al. Cyclic AMP-responsive element binding protein- and nuclear factor-kappaB-regulated CXC chemokine gene expression in lung carcinogenesis. Cancer Prev. Res. 2008, 1, 316–328.
109.
Zhu, L.; Zhou, K.X.; Ma, M.Z.; et al. Tuftelin 1 Facilitates Hepatocellular Carcinoma Progression through Regulation of Lipogenesis and Focal Adhesion Maturation. J. Immunol. Res. 2022, 2022, 1590717.
110.
Steven, A.; Leisz, S.; Massa, C.; et al. HER-2/neu mediates oncogenic transformation via altered CREB expression and function. Mol. Cancer Res. 2013, 11, 1462–1477.
111.
Lee, J.W.; Park, H.S.; Park, S.A.; et al. A Novel Small-Molecule Inhibitor Targeting CREB-CBP Complex Possesses Anti-Cancer Effects along with Cell Cycle Regulation, Autophagy Suppression and Endoplasmic Reticulum Stress. PLoS ONE 2015, 10, e0122628.
112.
Li, B.X.; Xiao, X. Discovery of a small-molecule inhibitor of the KIX-KID interaction. Chembiochem 2009, 10, 2721–2724.
113.
Li, B.X.; Yamanaka, K.; Xiao, X. Structure-activity relationship studies of naphthol AS-E and its derivatives as anticancer agents by inhibiting CREB-mediated gene transcription. Bioorg. Med. Chem. 2012, 20, 6811–6820.
114.
Jiang, M.; Yan, Y.; Yang, K.; et al. Small molecule nAS-E targeting cAMP response element binding protein (CREB) and CREB-binding protein interaction inhibits breast cancer bone metastasis. J. Cell Mol. Med. 2019, 23, 1224–1234.
115.
Li, B.X.; Gardner, R.; Xue, C.; et al. Systemic Inhibition of CREB is Well-tolerated in vivo. Sci. Rep. 2016, 6, 34513.
116.
Xie, F.; Li, B.X.; Kassenbrock, A.; et al. Identification of a Potent Inhibitor of CREB-Mediated Gene Transcription with Efficacious in Vivo Anticancer Activity. J. Med. Chem. 2015, 58, 5075–5087.
117.
Xie, F.; Fan, Q.; Li, B.X.; et al. Discovery of a Synergistic Inhibitor of cAMP-Response Element Binding Protein (CREB)-Mediated Gene Transcription with 666-15. J. Med. Chem. 2019, 62, 11423–11429.
118.
Peng, J.; Miller, M.; Li, B.X.; et al. Design, Synthesis and Biological Evaluation of Prodrugs of 666-15 as Inhibitors of CREB-Mediated Gene Transcription. ACS Med. Chem. Lett. 2022, 13, 388–395.
119.
Mitton, B.; Chae, H.D.; Hsu, K.; et al. Small molecule inhibition of cAMP response element binding protein in human acute myeloid leukemia cells. Leukemia 2016, 30, 2302–2311.
120.
Chae, H.D.; Cox, N.; Capolicchio, S.; et al. SAR optimization studies on modified salicylamides as a potential treatment for acute myeloid leukemia through inhibition of the CREB pathway. Bioorg. Med. Chem. Lett. 2019, 29, 2307–2315.
121.
Vinson, C.; Myakishev, M.; Acharya, A.; et al. Classification of human B-ZIP proteins based on dimerization properties. Mol. Cell Biol. 2002, 22, 6321–6335.
122.
Rishi, V.; Potter, T.; Laudeman, J.; et al. A high-throughput fluorescence-anisotropy screen that identifies small molecule inhibitors of the DNA binding of B-ZIP transcription factors. Anal. Biochem. 2005, 340, 259–271.
123.
Zhao, J.; Stagno, J.R.; Varticovski, L.; et al. P6981, an arylstibonic acid, is a novel low nanomolar inhibitor of cAMP response element-binding protein binding to DNA. Mol. Pharmacol. 2012, 82, 814–823.
124.
Cho, Y.S.; Kim, M.K.; Cheadle, C.; et al. A genomic-scale view of the cAMP response element-enhancer decoy: A tumor target-based genetic tool. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 15626–15631.
125.
Park, S.I.; Park, S.J.; Lee, J.; et al. Inhibition of cyclic AMP response element-directed transcription by decoy oligonucleotides enhances tumor-specific radiosensitivity. Biochem. Biophys. Res. Commun. 2016, 469, 363–369.
126.
Uchida, D.; Saito, Y.; Kikuchi, S.; et al. Development of gene therapy with a cyclic adenosine monophosphate response element decoy oligodeoxynucleotide to prevent vascular intimal hyperplasia. J. Vasc. Surg. 2020, 71, 229–241.
127.
Chowdhury, M.A.R.; An, J.; Jeong, S. The Pleiotropic Face of CREB Family Transcription Factors. Mol. Cells 2023, 46, 399–413.
128.
Dinevska, M.; Widodo, S.S.; Cook, L.; et al. CREB: A multifaceted transcriptional regulator of neural and immune function in CNS tumors. Brain Behav. Immun. 2024, 116, 140–149.
129.
Teich, A.F.; Nicholls, R.E.; Puzzo, D.; et al. Synaptic therapy in Alzheimer’s disease: A CREB-centric approach. Neurotherapeutics 2015, 12, 29–41.
Issue
Volume 3, Issue 2How to Cite
Jin, Q., Jiang, Y., Zhang, Z., Yang, Y., Fu, Z., Gao, Y., Li, N., He, Y., & Li, C. (2024). The Role of the CREB Signaling Pathway in Tumor Development and Therapeutic Potential. International Journal of Drug Discovery and Pharmacology, 3(2), 100011. https://doi.org/10.53941/ijddp.2024.100011
RIS
BibTex
Copyright & License
Copyright (c) 2024 by the authors.
This work is licensed under a This work is licensed under a Creative Commons Attribution 4.0 International License.